Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry.
Zhang Rui-Yan,Zhang Qi,Zhu Jin-Zhou,Chen Liang-Long,Zhang Chen-Yun,Zhou Xu-Chen,Yuan Yong,Zhong Zhi-Xiong,Li Lang,Qiu Jian,Wang Wei,Chen Xi-Ming,Yang Zhi-Jian,Yan Jin-Chuan,Chen Shao-Liang,Hou Yu-Qing,Wu Yan-Qing,Luo Hai-Ming,Qiu Jian-Ping,Zhu Li,Wang Yan,Fu Guo-Sheng,Wang Jian-An,Ma Kang-Hua,Yin Yue-Hui,Zhang Dai-Fu,Hu Xue-Song,Zhu Guo-Ying,Shen Wei-Feng,null null
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2011.21.016
IF: 6.133
2011-01-01
Chinese Medical Journal
Abstract:Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention (PCI). The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of >= 1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate cif composite major adverse cardiac events (MACE) and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 (98.7%) patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients (0.78%) had cardiac death, 6 (0.58%) suffered non-fatal myocardial infarction, and 46 (4.46%) underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 (0.97%) patients, and the rate of Academic Research Consortium (ARC) definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation. Chin Med J 2011;124(21):3521-3526